CAESAREA, Israel – July 2, 2014 – Mazor Robotics Ltd., a developer of innovative guidance systems and complementary products, announced today that it has received the first order for its Renaissance system since the commercial launch of the brain surgery module.
The system was sold to Bryan Medical Center in Lincoln, NE and will be utilized for spine and brain procedures. Bryan Medical Center is a 640-bed, not-for-profit, locally owned and governed health care organization serving patients from throughout Nebraska, as well as parts of Kansas, Iowa, South Dakota and other states in the region.
“The first order for Renaissance with our brain surgery module is a new milestone for Mazor Robotics. The value proposition offered to our customers enabled our team to achieve the first system placement in the U.S., less than three months after we commercially launched the brain application,” commented Ori Hadomi, Chief Executive Officer. “The versatility of the Renaissance system enables surgeons and hospital administrators to deploy a single proven system for both brain and spine procedures.”
The Company commercially launched the brain application at the American Association of Neurological Surgeons (AANS) annual meeting in April 2014. Renaissance’s brain module is primarily used to assist with Deep Brain Stimulation (DBS) procedures to treat movement disorders, such as Parkinson’s disease. Three other hospitals, including Littleton Adventist (Littleton, CO), were utilizing the brain application during a pre-launch testing period and continue to use the system for brain surgeries.
About Mazor
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visitwww.MazorRobotics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expectations for growth in system sales and recurring revenue, the Company’s expected sales in 2016, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.
U.S. Contacts: EVC Group
Michael Polyviou/Doug Sherk – Investors
mpolyviou@evcgroup.com; dsherk@evcgroup.com
212.850.6020; 646-445-4800
David Schemelia – Media
646.201.5431
